Free 4-week trial

Taken at bedtime for high levels upon waking before patients’
first levodopa dose

GOCOVRI® QHS (once at bedtime) uses a time-dependent approach that's designed to provide an initial lag, a slow rise in amantadine concentration during the night, and a high concentration in the morning
through the entire waking day—when symptoms occur1,2

Gocovri® QHS reaches high concentrations after ~8 hours1,2

An initial lag in amantadine concentration A slow rise in amantadine concentration during the night A high amantadine concentration from the morning throughout the entire waking day

Pharmacokinetic data do not provide evidence of clinical safety or efficacy.
These simulated data are derived from a steady-state PK study using the 137 mg QHS dose of GOCOVRI®.


See appropriate dosing ›


GOCOVRI® QHS—starting and staying on the appropriate dose

Care should be taken in dose selection. Amantadine is excreted by the kidney. The majority of patients with PD are elderly and more likely to have decreased renal function1

GOCOVRI QHS: Dosing Options when Starting & Staying on GOCOVRI

If a dose is missed, the next dose should be taken as scheduled.1


Administration & discontinuation

Administration1

  • GOCOVRI® can be taken with or without food
  • GOCOVRI® can be administered by carefully opening the capsule and sprinkling the entire contents in 1 teaspoon of soft food, such as applesauce
  • Concomitant use of GOCOVRI® with alcohol is not recommended

Discontinuation1

  • Because rapid dose reduction or withdrawal may cause adverse reactions, it is recommended to avoid sudden discontinuation of GOCOVRI®
  • To avoid sudden discontinuation, patients who have taken GOCOVRI® for more than 4 weeks should reduce their dose by half during their final week of dosing

Register for gocovri® updates

Sign up to stay informed, or call 1-844-GOCOVRI and learn more about GOCOVRI® in your area.

Specialty*:
*Required
I authorize Adamas Pharmaceuticals, Inc., its affiliates, and its agents to communicate with me by email with information pertaining to Adamas products and services. I understand that I may revoke this authorization and choose not to receive information from Adamas by clicking the "unsubscribe" link at the bottom of the emails I receive from Adamas.

Thank you

Your registration is complete and you are now signed up to receive updates on GOCOVRI® (amantadine) extended release capsules. An email will be sent to your inbox confirming your registration.

You can also call 1-844-GOCOVRI to learn more about GOCOVRI® in your area.

Important Safety Information

Indication

GOCOVRI® (amantadine) extended release capsules is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Contraindications

GOCOVRI is contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m2.

Warnings and Precautions

Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson’s disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities.

Suicidality and Depression: Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression.

Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases.

Dizziness and Orthostatic Hypotension: Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose.

Withdrawal-Emergent Hyperpyrexia and Confusion: Rapid dose reduction or abrupt discontinuation of GOCOVRI, may cause an increase in the symptoms of Parkinson’s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. Avoid sudden discontinuation of GOCOVRI.

Impulse Control/Compulsive Behaviors: Patients may experience urges (e.g. gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications.

Adverse Reactions

The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and orthostatic hypotension.

View the full Prescribing Information.

Indication

GOCOVRI® (amantadine) extended release capsules is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

References: 1. GOCOVRI® (amantadine) [Prescribing Information]. Emeryville, CA: Adamas Pharma LLC; 2017. 2. Hauser RA, Pahwa R, Wargin WA, et al. Pharmacokinetics of ADS-5102 (amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia. Clin Pharmacokinet. 2019;58(1):77-88.